Drug essentials mTOR inhibitors.
Wilkes
Gail M
GM
Boston Medical Center, Boston, Massachusetts, USA.
D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D004347:Drug Interactions; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D011494:Protein Kinases / Q000378:metabolism*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; C515074:ridaforolimus; C401859:temsirolimus; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus